MyFinsight
Home
Blog
About
Redemption of short-term
investments
$156,466K
(451.88%↑ Y/Y)
Proceeds from exercise of
series a warrants, net...
$9,116K
Acquisition of short-term
investments
-$18K
(-101.95%↓ Y/Y)
Net cash provided by
investing activities
$111,992K
(157.29%↑ Y/Y)
Cash provided by
financing activities
$9,133K
(5089.20%↑ Y/Y)
Canceled cashflow
$44,492K
Net increase in cash
and cash...
$98,411K
(472.66%↑ Y/Y)
Canceled cashflow
$22,714K
something is missing
-$44,466K
Acquisition of property and
equipment
$26K
(52.94%↑ Y/Y)
Non-cash interest
expense related to...
$3,705K
Accrued liabilities
$2,428K
License receivable
-$1,546K
Share-based compensation
expense
$1,338K
(-49.68%↓ Y/Y)
Non-cash interest
expense related to...
$897K
(-46.54%↓ Y/Y)
Other receivables
-$699K
(-23.50%↓ Y/Y)
Deferred revenue
$618K
Prepaid expenses
-$175K
(83.97%↑ Y/Y)
Amortization of debt costs
$118K
(-43.27%↓ Y/Y)
Depreciation of property and
equipment
$57K
(3.64%↑ Y/Y)
Net cash used in
operating activities
-$22,714K
(14.34%↑ Y/Y)
Canceled cashflow
$11,581K
Net loss
-$28,614K
(15.16%↑ Y/Y)
Inventory
$2,896K
Accounts payable
-$1,569K
Accounts receivable, net
$1,115K
Research and development
tax credits...
$90K
(-49.44%↓ Y/Y)
Operating lease assets and
liabilities
-$11K
(-266.67%↓ Y/Y)
Back
Back
Cash Flow
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)
source: myfinsight.com